CA19-9 Assay Portfolio Service
Creative Biolabs offers a comprehensive carbohydrate antigen 19-9 (CA19-9) assay portfolio service to support targeted cancer therapy and diagnosis. We utilize advanced technologies and leverage our experienced scientists to accurately assess CA19-9. This is a well-known, critical tumor marker for the detection of digestive tract carcinomas and is essential for screening and monitoring pancreatobiliary cancer. Our service delivers precise and reliable data, providing crucial insights into disease progression and supporting the development of novel therapeutic and diagnostic strategies.
Background What We Can Offer Why Choose Us FAQs Customer Review Related Services Contact Us
The Strategic Importance of CA19-9 in Modern Diagnostics
CA19-9 (sialyl Lewis-a) is a tumor-associated carbohydrate antigen produced through aberrant glycosylation, a hallmark of cancer. It arises from the epigenetic silencing of a specific sialyltransferase enzyme, which prevents the synthesis of its normal counterpart and leads to CA19-9 accumulation. Primarily used in pancreatic ductal adenocarcinoma (PDAC), CA19-9 serum levels serve as a crucial biomarker. While not reliable for general screening or diagnosis due to its presence in other conditions, it is highly valuable for assessing clinical stage, determining surgical resectability, evaluating prognosis, and monitoring response to chemotherapy. Furthermore, rising CA19-9 levels after surgery are a strong predictor of postoperative recurrence.
A Multi-Platform Approach
Our portfolio leverages cutting-edge technologies to overcome the traditional limitations of CA19-9 detection. We specialize in developing and optimizing a range of assay formats, tailored to your specific needs.
Discover How We Can Help - Request a Consultation
Why Choose Us?
Our multi-platform approach, which leverages cutting-edge technologies like ELISA, ensures exceptional sensitivity and specificity that go beyond single-platform limitations. At Creative Biolabs, we prioritize the quality of our components, providing a curated selection of high-affinity antibodies and conjugates to guarantee minimal cross-reactivity and robust signal generation. Our nearly two decades of experience and unwavering commitment to scientific rigor mean we are not just a service provider, but a strategic partner dedicated to your project's success. We combine deep expertise with cutting-edge technology to deliver the results you can trust.
Ready to advance your project with confidence? Experience the Creative Biolabs Advantage - Get a Quote Today.
FAQs
Q1: How does your service address the false-positive results associated with CA19-9?
A1: We offer a comprehensive, multi-platform approach to CA19-9 analysis that minimizes false positives. We design studies to account for variables like benign conditions and genetic variations, ensuring a more accurate and reliable assessment.
Q2: What is the benefit of a multi-platform approach compared to a single-platform assay
A2: By offering a portfolio of platforms like ELISA, we overcome the limitations of a single assay. This ensures we select the best technology for your needs, providing optimal performance and confidence.
Q3: Can your service help us develop a combination biomarker panel
A3: Absolutely. We provide expert guidance on developing and validating panels that combine CA19-9 with other markers. This synergistic approach enhances both diagnostic accuracy and predictive power, a critical strategy in modern immuno-oncology.
Customer Review
-
Tangible Improvement in Data Quality
Integrating Creative Biolabs' CA19-9 assay significantly enhanced our trial data. Their superior platform sensitivity and rigorous quality control reliably detected subtle, previously missed, post-treatment biomarker changes. - Mar* **D
-
Precision and Specificity in Antibody Selection
The precision and specificity of the antibodies Creative Biolabs provided for our sandwich immunoassay were excellent. We were able to confirm our initial findings and move on to the next phase of our project with confidence. - Rob* **S
Related Services
In addition to our core CA19-9 assay portfolio, Creative Biolabs offers a range of complementary services to accelerate your research:
Cell-based Antagonist Assay Services
Creative Biolabs employs cell-based antagonist assays to understand how drugs interact within cellular environments. These assays provide precise, high-throughput solutions to evaluate ligand-receptor interactions, signaling pathways, and downstream cellular events.
Learn More →
Drug Bioanalysis Service
Creative Biolabs offers comprehensive drug bioanalysis services for pharmaceutical companies, leveraging over 20 years of experience to provide accurate data for the pharmacokinetic and pharmacodynamic characterization of drugs.
Learn More →
Contact Us
At Creative Biolabs, our CA19-9 assay portfolio service is a gateway to actionable clinical insights, driven by scientific rigor and tailored expertise. By partnering with us, you gain a dedicated team committed to helping you translate scientific discovery into tangible clinical impact.
